IO Biotech(IOBT) - 2024 Q1 - Quarterly Results

Exhibit 99.1 IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights New York, NY – May 14, 2024: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024. "This will be a transformative year for IO Biotech as we approach the interim analysis of our pivotal Phase 3 study in first-line advanced m ...